Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Human coagulation factor VIII (FVIII) is a key co-factor in the clotting cascade, the deficiency of which leads to Hemophilia A. Human plasma-derived (pdFVIII) and recombinant FVIII (rFVIII) had been used as effective products to prevent and treat bleeding episodes. Both FVIII products share identical amino acid sequences and appear to be equivalent as of clinical efficiency. However, systemic reviews found an increased risk of neutralizing antibody (or inhibitor) development with recombinant products. FVIII is a highly glycosylated protein, and its glycosylation pattern is specific to host cells and environments. The roles of glycosylation in immune responses toward pdFVIII and rFVIII are yet to be defined. Herein, we systemically profiled N- and O-glycomes of pdFVIII and rFVIII using a mass spectrometry-based glycoproteomic strategy. A total of 110 site-specific N-glycopeptides consisting of 61 N-glycoforms were identified quantitatively from rFVIII and pdFVIII. Additionally, 31 O-glycoforms were identified on 23 peptides from rFVIII and pdFVIII. A comprehensive comparison of their site-specific glycan profiles revealed distinct differences between the glycosylation of pdFVIII and rFVIII.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244179 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233576 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry.
Haemophilia
May 2025
School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Background: The last 15 years have seen new extended half-life (EHL) recombinant FVIII/IX concentrates and nonreplacement therapy for haemophilia A (emicizumab) introduced in Europe. These changes affect FVIII/IX exposure in previously untreated patients (PUPs) and previously treated patients (PTPs) with severe haemophilia A and B (SHA and SHB) and may modify inhibitor development and/or detection.
Aim: To report trends in treatment for severe haemophilia and concomitant changes in inhibitor incidence.
Advances in biopharmaceutical products for hemophilia.
iScience
December 2024
Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu 610041, China.
Hemophilia is caused by the deficiency of clotting factors due to a single genetic abnormality. Replacement therapies have evolved from plasma-derived to recombinant coagulation factor concentrates but continue to have certain limitations. Monoclonal antibodies are clinical prophylactic treatment options unaffected by inhibitors and have better compliance than coagulation factor concentrates for patients with hemophilia.
View Article and Find Full Text PDFInhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study.
Res Pract Thromb Haemost
November 2024
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Background: The SIPPET randomized clinical trial showed that in previously untreated patients (PUPs) with severe hemophilia A, treatment with plasma-derived factor (F)VIII (pdFVIII) within the first 50 exposure days (EDs) was associated with a lower cumulative incidence of inhibitors than with recombinant FVIII (rFVIII). Switching to rFVIII beyond 50 EDs with pdFVIII is a treatment often implemented by many centers. The question is whether or not this switch may induce a risk of inhibitor development.
View Article and Find Full Text PDFReal-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization.
Blood Res
October 2024
CliCon S.r.l. Società Benefit, Health, Economics & Outcomes Research, Bologna, Italy.
Article Synopsis
- This study looked at how people with Hemophilia A in Italy use different types of Factor VIII medicines between 2017 and 2022.
- It found that many patients prefer using extended half-life (EHL) Factor VIII products, especially during preventative treatment.
- The results showed that using EHL products may help doctors provide better protection against bleeding for patients with hemophilia.
Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A.
Drugs Real World Outcomes
September 2024
Pfizer Japan Inc., Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, Japan.
Article Synopsis
- Treatment options for haemophilia A have expanded beyond traditional plasma-derived and standard recombinant factors to include newer extended half-life and non-factor alternatives.
- A study analyzing data from 2016-2020 showed an increase in outpatient use of these newer treatments, as well as a significant rise in healthcare and drug expenditures for Japanese patients.
- Although many patients switched from standard to extended half-life products, overall spending continued to increase without clear benefits in FVIII prescribing patterns post-switch.